You are living in a dream world if you expect revenue in excess of $10-15M in 2025 without reimbursement approval, which will happen by mid 2026 at best. At their current burn rate, their expenses will be $60M per year. But its likely to go up to close to $100M if they have even modest ambition of scaling commercially in the UK. So they are still going to be $70-80M short. Where will that money come from? Thats not even considering the costs to start another combo trial or two. They will be forced to dilute a ton of shares and I wouldn't be surprised if they beg shareholders to raise the authorized count around mid next year.
Market Data 
Markets 
AI
